Montelukast
Other / unclassified targets ACE2, CYP2C8, CYSLTR1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (7) | US (FDA) | SINGULAIR | — | 2000-03-03 – 2012-03-26 | fda.gov ↗ |
| Approved | US (FDA) | SINGULAIR | — | 1998-02-20 | fda.gov ↗ |
Trials 197 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT07409714 | Jul 2026 → Feb 2030 expected | type 2 diabetes mellitus | University of Colorado, Denver | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06887673 | Mar 2025 → Mar 2026 overdue | brain neoplasm, colorectal cancer, endometrial cancer, ovarian cancer +1 | University of South Florida | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04572256 | Feb 2021 → Jun 2027 expected | osteoarthritis, knee | Austin V Stone | Recruiting | No outcome recorded |
| Phase 0 | NCT04075110 | Jul 2019 → Jun 2022 | type 2 diabetes mellitus | Sadat City University | Completed | No outcome recorded |
| Phase 0 | NCT04077892 | Jun → Sep 2016 | allergic rhinitis | Beijing Tongren Hospital | Completed | No outcome recorded |
| Phase 126 trials | ||||||
| Phase 1 | NCT05992311 | Aug 2025 → Apr 2028 expected | persian gulf syndrome | Baylor College of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05852769 | May → Aug 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05607446 | Sep 2022 → May 2023 | allergic rhinitis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT04425902 | Dec 2020 → Mar 2021 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT04474327 | Jul 2020 → Feb 2021 | neonatal sepsis | Mansoura University Children Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04275115 | Feb → Apr 2020 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT04097951 | Nov 2019 → Jan 2020 | respiratory system disorder | Hyundai Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT03371849 | Jul → Aug 2017 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT03131973 | May → Nov 2017 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02762123 | May → Aug 2016 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02578277 | Nov → Dec 2015 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02456844 | May → Jul 2015 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02322671 | Feb → Apr 2015 | respiratory system disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02321748 | Dec 2014 → Apr 2015 | — | Maruho Europe Limited | Completed | No outcome recorded |
| Phase 1 | NCT02227173 | Sep → Nov 2014 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02045966 | Feb → Apr 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02029313 | Nov 2013 → Jan 2014 | allergic respiratory disease | PharmaKing | Completed | No outcome recorded |
| Phase 1 | NCT01621386 | Jan 2013 → Sep 2015 | asthma | Hal C Charles | Completed | No outcome recorded |
| Phase 1 | NCT01651481 | Jul → Sep 2012 | rhinitis | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT01061333 | Jun 2010 → Feb 2011 | asthma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01086527 | Mar 2010 → Sep 2014 | asthma | Nemours Children's Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00739297 | Jul → Dec 2008 | chronic asthma | Organon and Co | Completed | No outcome recorded |
| Phase 1 | NCT00511316 | Aug 2007 → Sep 2015 | eosinophilic esophagitis | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00636207 | Aug 2007 → Sep 2008 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 1 | NCT00492102 | Mar 2007 → Jun 2011 | bronchopulmonary dysplasia | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1 | NCT00273013 | Nov 2004 → Oct 2005 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07101640 | Feb 2026 → Jun 2027 expected | bronchopulmonary dysplasia | Duke University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05143502 | Jan 2022 → Jan 2024 | chronic rhinosinusitis | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04080947 | Aug 2019 → Aug 2021 | metabolic dysfunction-associated steatohepatitis | Sadat City University | Completed | No outcome recorded |
| Phase 226 trials | ||||||
| Phase 2 | NCT03277170 | Sep 2025 → Aug 2028 | acute asthma, childhood onset asthma, status asthmaticus | Vanderbilt University Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT05819541 | Oct 2023 → Mar 2026 | status asthmaticus | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05663866 | May 2023 → Mar 2024 overdue | non-small cell lung carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05447520 | Dec 2021 → Dec 2022 | rheumatoid arthritis | Noha Mansour | Completed | No outcome recorded |
| Phase 2 | NCT04718285 | May 2021 → May 2022 | COVID-19 | Bahçeşehir University | Unknown | No outcome recorded |
| Phase 2 | NCT04198623 | Mar 2020 → Jul 2024 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT03991988 | Sep 2019 → Nov 2022 | Alzheimer disease | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT04374981 | Jul → Nov 2019 | — | Damanhour University | Completed | No outcome recorded |
| Phase 2 | NCT03794037 | Dec 2018 → Dec 2023 | ovarian hyperstimulation syndrome | Benha University | Suspended | No outcome recorded |
| Phase 2 | NCT03402503 | Nov 2018 → Mar 2024 | Alzheimer disease | IntelGenx Corp. | Completed | No outcome recorded |
| Phase 2 | NCT02352545 | Aug 2014 → Aug 2015 | — | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01960413 | Nov 2013 → Mar 2018 | sickle cell disease | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01804400 | Oct 2012 → Oct 2013 | allergic rhinitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01656395 | Aug 2012 → Jun 2014 | asthma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02108886 | Dec 2011 → Jul 2014 | — | University of Sherbrooke | Unknown | No outcome recorded |
| Phase 2 | NCT01717625 | Nov 2011 → Oct 2013 | bronchopulmonary dysplasia | Ajou University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01432080 | Sep 2011 → Dec 2012 | bronchiolitis obliterans syndrome, cryptogenic organizing pneumonia | Maisonneuve-Rosemont Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01307462 | Jun 2011 → Sep 2014 | transplant-related bronchiolitis obliterans | Stephanie Lee | Completed | No outcome recorded |
| Phase 2 | NCT01241422 | Nov 2010 → Jun 2011 | asthma | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00947453 | Jul 2009 → Dec 2011 | asthma | University of East Anglia | Completed | No outcome recorded |
| Phase 2 | NCT00656058 | Jun 2008 → May 2014 | chronic graft versus host disease, transplant-related bronchiolitis obliterans | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00213252 | Sep 2005 → Feb 2008 | asthma | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 2 | NCT00394160 | Dec 2004 → Oct 2005 | bronchiolitis | Organon and Co | Completed | No outcome recorded |
| Phase 2 | NCT00783601 | Oct 2004 → May 2005 | asthma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00446186 | Feb → Mar 2004 | allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 2 | NCT00394069 | Jul → Dec 2003 | bronchiolitis | Organon and Co | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT06747130 | Jan 2025 → Jan 2027 expected | dengue disease | Phramongkutklao College of Medicine and Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04389411 | Nov 2022 → Jan 2023 | COVID-19 | McGill University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05293132 | Feb 2022 → Jun 2023 | infectious disease with sepsis | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT04673422 | Jan 2021 → Jun 2023 | dengue shock syndrome | Phramongkutklao College of Medicine and Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00115297 | Sep 2004 → Oct 2016 | asthma, lung disorder | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 357 trials | ||||||
| Phase 3 | NCT07320625 | Feb 2026 → Feb 2027 expected | ST-elevation myocardial infarction | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05894577 | Jan → Jul 2023 | COVID-19 | Susanna Naggie, MD | Completed | No outcome recorded |
| Phase 3 | NCT05362474 | Jul 2022 → Jun 2023 | diabetic kidney disease | University of Colorado, Denver | Terminated | No outcome recorded |
| Phase 3 | NCT04695704 | Aug 2021 → Jul 2023 | COVID-19, severe acute respiratory syndrome | Jordi Gol Institute for Primary Care Research | Terminated | No outcome recorded |
| Phase 3 | NCT04885530 | Jun 2021 → Apr 2024 | COVID-19 | Susanna Naggie, MD | Completed | No outcome recorded |
| Phase 3 | NCT04277702 | May 2020 → Oct 2023 | atherosclerosis, limb ischemia, peripheral arterial disease | Jagiellonian University | Unknown | No outcome recorded |
| Phase 3 | NCT03545997 | Nov 2019 → Mar 2020 | obstructive sleep apnea syndrome | University Hospital, Grenoble | Terminated | No outcome recorded |
| Phase 3 | NCT04324918 | Oct 2018 → Jun 2019 | perennial allergic rhinitis | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT02793375 | Aug 2018 → Nov 2024 | — | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 3 | NCT02541760 | Apr 2014 → Mar 2015 | otitis media with effusion | Hormozgan University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01857063 | Jun → Sep 2013 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01852812 | Jun → Dec 2013 | perennial allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01606306 | Feb 2013 → Apr 2015 | asthma | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01673620 | Jul → Oct 2012 | allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01640535 | Jun 2012 → Feb 2013 | perennial allergic rhinitis | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT00540839 | Nov 2007 → Mar 2008 | asthma | Organon and Co | Withdrawn | No outcome recorded |
| Phase 3 | NCT00551382 | Nov 2007 → Dec 2009 | viral respiratory tract infection | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00442338 | Mar → Aug 2007 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00395304 | Mar 2007 → Dec 2011 | asthma | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00423995 | Nov 2006 → Mar 2007 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00755794 | Jun 2006 → Sep 2007 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00461032 | Jun → Nov 2006 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00284856 | May 2006 → Apr 2010 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00319995 | Mar → Jun 2006 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00289874 | Mar 2006 → Jul 2007 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00245570 | Dec 2005 → Sep 2006 | exercise-induced bronchoconstriction | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00127166 | Dec 2005 → Nov 2008 | exercise-induced bronchoconstriction | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00445107 | Nov 2005 → May 2006 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00328718 | Oct 2005 → Apr 2007 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00229970 | Sep 2005 → Oct 2006 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00398151 | Aug 2005 → Jan 2006 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00252863 | Dec 2004 → May 2006 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00127647 | Nov 2004 → Apr 2005 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00771160 | Sep 2004 → Feb 2005 | allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092989 | Jul 2004 → Mar 2007 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00090142 | May → Oct 2004 | exercise-induced bronchoconstriction | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092144 | Feb → Jun 2004 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092118 | Oct 2003 → May 2004 | perennial allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00076973 | Aug 2003 → Jun 2006 | respiratory syncytial virus bronchiolitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092131 | Jun → Nov 2003 | exercise-induced bronchoconstriction | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00116324 | Apr 2003 → Dec 2006 | asthma | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00092885 | Mar → Oct 2003 | asthma, seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092105 | Apr 2002 → Jan 2003 | asthma, perennial allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00045955 | Feb 2002 → Nov 2003 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00974571 | Nov 2001 → May 2002 | perennial allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00489346 | Oct 2001 → Jun 2002 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00963469 | Aug → Nov 2001 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00943397 | Apr → Oct 2001 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00972738 | Apr → Jul 2001 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00968149 | Mar → Jun 2001 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00700661 | Jan 2001 → Dec 2002 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00960141 | Aug → Oct 2000 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00979901 | Mar → May 2000 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00162864 | Dec 1999 → Apr 2002 | asthma, chronic obstructive pulmonary disease | Kaiser Permanente | Completed | No outcome recorded |
| Phase 3 | NCT00963599 | Sep → Nov 1999 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00968201 | Dec 1997 → Mar 2001 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00911547 | Mar 1995 → Apr 1996 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 453 trials | ||||||
| Phase 4 | NCT07685886 | Sep 2026 → Jun 2031 expected | kidney disorder, retinal disorder, type 2 diabetes mellitus, vascular disorder | University of Colorado, Denver | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05498116 | Jan 2023 → Feb 2027 expected | proteinuria | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 4 | NCT05651750 | Nov 2022 → May 2023 | — | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT05094596 | Oct → Dec 2021 | pneumonia | Bugra Kerget | Unknown | No outcome recorded |
| Phase 4 | NCT04815187 | Jun 2021 → Sep 2025 overdue | Meniere disease, allergic rhinitis | House Ear Institute | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04957927 | Dec 2020 → Sep 2021 | allergic rhinitis | Usama Azhar | Unknown | No outcome recorded |
| Phase 4 | NCT04537780 | Aug 2019 → Aug 2020 | metabolic dysfunction-associated steatohepatitis | Tanta University | Completed | No outcome recorded |
| Phase 4 | NCT03380975 | Aug 2018 → Mar 2019 | allergic respiratory disease | Clinision | Completed | No outcome recorded |
| Phase 4 | NCT03269318 | Jul 2017 → Aug 2019 | asthma | Brighton and Sussex University Hospitals NHS Trust | Terminated | No outcome recorded |
| Phase 4 | NCT03096327 | May → Dec 2017 | asthma | PharmEvo Pvt Ltd | Completed | No outcome recorded |
| Phase 4 | NCT02761252 | Apr → Nov 2016 | asthma, seasonal allergic rhinitis | Menarini International Operations Luxembourg SA | Completed | No outcome recorded |
| Phase 4 | NCT02655562 | Apr 2016 → Dec 2024 | — | Beijing Chao Yang Hospital | Suspended | No outcome recorded |
| Phase 4 | NCT02635334 | Nov 2015 → Jun 2016 | asthma | Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C. | Completed | No outcome recorded |
| Phase 4 | NCT02534467 | Jul 2015 → Dec 2018 | atopic eczema | Murdoch Childrens Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02410278 | Mar 2015 → Feb 2017 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT02110654 | Jun 2014 → Nov 2020 | asthma, nasal cavity polyp, sinusitis | First Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 4 | NCT02565212 | May → Oct 2014 | allergic rhinitis | Istanbul Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02551536 | Apr 2014 → Apr 2015 | allergic rhinitis | Indira Gandhi Medical College, Shimla | Completed | No outcome recorded |
| Phase 4 | NCT02401256 | Jul 2013 → May 2016 | — | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT01279668 | May 2011 → Oct 2012 | pertussis | University of Oxford | Unknown | No outcome recorded |
| Phase 4 | NCT01211509 | Oct 2010 → Mar 2015 | bronchiolitis obliterans syndrome, transplant rejection | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT01147510 | Jul 2010 → Sep 2012 | chronic asthma | Ajou University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00699062 | Jan 2010 → Jan 2012 | asthma | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00775697 | Sep 2009 → Dec 2013 | asthma | University of Verona | Unknown | No outcome recorded |
| Phase 4 | NCT00770900 | Sep 2008 → Dec 2009 | asthma | University of Brasilia | Completed | No outcome recorded |
| Phase 4 | NCT00557284 | Mar 2008 → May 2009 | atopic eczema | 1st Allergy & Clinical Research Center | Completed | No outcome recorded |
| Phase 4 | NCT00534976 | Feb 2008 → Mar 2010 | exercise-induced bronchoconstriction | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00453765 | Dec 2007 → Sep 2010 | cough variant asthma, reactive airway disease | Isala | Completed | No outcome recorded |
| Phase 4 | NCT00545844 | Apr 2007 → Jan 2008 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00712335 | Feb 2007 → May 2011 | environmental induced asthma | Inje University | Completed | No outcome recorded |
| Phase 4 | NCT01725360 | Jan 2007 → Dec 2011 | asthma | Cantonal Hosptal, Baselland | Completed | No outcome recorded |
| Phase 4 | NCT00406094 | Nov 2006 → Dec 2009 | rhinitis | Bernstein, Jonathan A., M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT00295022 | Jul → Oct 2006 | seasonal allergic rhinitis | UCB Pharma | Completed | No outcome recorded |
| Phase 4 | NCT00832455 | Jun 2006 → Oct 2008 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00471809 | Mar 2006 → Mar 2007 | asthma | National Heart, Lung, and Blood Institute (NHLBI) | Terminated | No outcome recorded |
| Phase 4 | NCT00721240 | Feb 2006 → Dec 2008 | asthma | Marien Hospital Wesel | Completed | No outcome recorded |
| Phase 4 | NCT00273689 | Dec 2005 → Sep 2007 | exercise-induced bronchoconstriction | University of New Mexico | Completed | No outcome recorded |
| Phase 4 | NCT00196547 | Sep → Nov 2005 | asthma | Firestone Institute for Respiratory Health | Completed | No outcome recorded |
| Phase 4 | NCT00296530 | Sep 2005 → Jul 2007 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00380705 | Mar → Jul 2005 | allergic rhinitis, asthma | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00299910 | Mar 2005 → ? | sleep apnea syndrome | Soroka University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00442559 | Jan 2005 → Oct 2007 | allergic rhinitis, asthma | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00148408 | Dec 2003 → Dec 2005 | asthma | American Lung Association Asthma Clinical Research Centers | Completed | No outcome recorded |
| Phase 4 | NCT00446056 | Sep 2003 → Jun 2004 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00490243 | Jul 2003 → Oct 2006 | asthma | Medical University of Lodz | Completed | No outcome recorded |
| Phase 4 | NCT00756418 | Jun 2003 → Aug 2004 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00156819 | Jun 2003 → Aug 2005 | asthma | JHSPH Center for Clinical Trials | Completed | No outcome recorded |
| Phase 4 | NCT00157937 | Feb 2003 → Jun 2005 | allergic rhinitis, asthma | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00092092 | Oct 2002 → Jun 2004 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00545324 | Sep 2002 → Dec 2003 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00140881 | Jun 2000 → Feb 2003 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00395408 | Jun 2000 → Dec 2003 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00140946 | Mar 1998 → Oct 2000 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase not applicable22 trials | ||||||
| — | NCT04322422 | Jun 2020 → Jul 2022 | anxiety, asthma, depressive disorder, eosinophil disorder +1 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT04818723 | Feb 2019 → May 2020 | idiopathic nephrotic syndrome | Nishtar Medical University | Completed | No outcome recorded |
| — | NCT03039101 | Sep 2017 → Jul 2018 | allergic rhinitis | Mitchell Grayson | Completed | No outcome recorded |
| — | NCT02758873 | Feb 2016 → Jul 2019 | asthma | University of Sussex | Completed | No outcome recorded |
| — | NCT01967498 | Nov 2013 → Dec 2015 | conductive hearing loss disorder, otitis media with effusion | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT01770899 | Jan → Dec 2013 | status asthmaticus | Corrie Fletcher | Unknown | No outcome recorded |
| — | NCT01841164 | May 2012 → Jun 2014 | asthma | Karolinska University Hospital | Unknown | No outcome recorded |
| — | NCT01458418 | Dec 2011 → Feb 2015 | eosinophilic esophagitis | Children's Mercy Hospital Kansas City | Terminated | No outcome recorded |
| — | NCT01329939 | Apr 2011 → Sep 2014 | asthma, obesity disorder | Northwell Health | Completed | No outcome recorded |
| — | NCT01370187 | Jul 2010 → Apr 2011 | acute bronchiolitis, cough variant asthma | Hormozgan University of Medical Sciences | Completed | No outcome recorded |
| — | NCT01414868 | Mar → Sep 2010 | asthma | Guangzhou Institute of Respiratory Disease | Completed | No outcome recorded |
| — | NCT00903357 | Aug 2009 → Aug 2010 | atopic eczema | Pyun BokYang | Completed | No outcome recorded |
| — | NCT00863317 | Dec 2008 → Jul 2011 | bronchiolitis | Medical College of Wisconsin | Completed | No outcome recorded |
| — | NCT01055041 | Dec 2008 → Jun 2009 | chronic asthma | Government Medical College, Bhavnagar | Completed | No outcome recorded |
| — | NCT00814281 | May 2007 → Mar 2009 | lower respiratory tract disorder | Marywood University | Completed | No outcome recorded |
| — | NCT00424580 | Jan → Aug 2007 | asthma | University of Saskatchewan | Completed | No outcome recorded |
| — | NCT00406861 | Dec 2006 → Jun 2009 | erythema nodosum, leprosy | The Leprosy Mission Bangladesh | Unknown | No outcome recorded |
| — | NCT00375232 | Oct 2006 → ? | exercise-induced bronchoconstriction | Indiana University | Withdrawn | No outcome recorded |
| — | NCT00385463 | Apr 2006 → Apr 2007 | asthma, seasonal allergic rhinitis | Creighton University | Withdrawn | No outcome recorded |
| — | NCT00148603 | Sep 2005 → Dec 2006 | dyspepsia, eosinophilic gastroenteritis | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| — | NCT00353184 | Sep 2001 → Oct 2004 | acute asthma | Washington University School of Medicine | Terminated | No outcome recorded |
| — | NCT00943683 | Aug 2000 → Feb 2001 | asthma | Organon and Co | Completed | No outcome recorded |
Also used as a comparator or background therapy in 113 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05381207 Comparator | Oct 2022 → Oct 2024 | allergic rhinitis | Assiut University | Unknown | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT01998971 Background | Feb 2014 → Jan 2019 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01491503 Comparator | Nov 2011 → Jan 2012 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT00856687 Comparator | Apr → Dec 2009 | asthma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00664937 Comparator | May 2007 → Oct 2008 | exercise-induced bronchoconstriction | Organon and Co | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04294459 Background | Jun 2020 → May 2022 | immune system disorder | Sanofi | Terminated | No outcome recorded |
| Phase 227 trials | ||||||
| Phase 2 | NCT07537868 Comparator | Apr 2026 → May 2027 expected | acute myocardial infarction | October 6 University | Recruiting | No outcome recorded |
| Phase 2 | NCT06356571 Background | Mar 2025 → Jan 2027 expected | plasma cell myeloma | Sanofi | Recruiting | No outcome recorded |
| Phase 2 | NCT05922761 Background | May 2024 → Jun 2027 expected | chronic graft versus host disease, transplant-related bronchiolitis obliterans | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05896228 Background | Feb 2024 → Mar 2029 expected | plasma cell myeloma | Benjamin T Diamond, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT05807048 Background | Jun 2023 → Nov 2025 | lung cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT05704049 Background | Apr 2023 → Dec 2025 overdue | refractory plasma cell neoplasm | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04294641 Background | May 2021 → Jun 2024 | chronic graft versus host disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT04268498 Background | Feb 2020 → Feb 2027 expected | plasma cell myeloma | University of Miami | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02720081 Background | May 2016 → Aug 2017 | asthma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01730027 Comparator | Apr 2013 → Dec 2014 | asthma | Pulmagen Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01765192 Background | Feb → Oct 2013 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01615874 Comparator | Jan → Sep 2013 | asthma | Organon and Co | Withdrawn | No outcome recorded |
| Phase 2 | NCT01624974 Background | Aug 2012 → May 2014 | asthma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01551147 Comparator | Jun 2012 → Apr 2013 | asthma | Ono Pharma USA Inc | Completed | No outcome recorded |
| Phase 2 | NCT01536041 Comparator | Mar → Nov 2012 | asthma | Ono Pharma USA Inc | Completed | No outcome recorded |
| Phase 2 | NCT01424124 Comparator | Nov 2011 → Jun 2013 | asthma | Yuhan Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01437735 Comparator | Aug 2011 → Nov 2013 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01248975 Comparator | Dec 2010 → Oct 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01156792 Comparator | Sep 2010 → Oct 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01147744 Comparator | Jun 2010 → Oct 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01103349 Comparator | Apr 2010 → Aug 2011 | asthma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT01007721 Comparator | Oct 2009 → Apr 2010 | asthma, seasonal allergic rhinitis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00961155 Comparator | Aug 2009 → Dec 2013 | asthma | Medical University of Lodz | Unknown | No outcome recorded |
| Phase 2 | NCT00936624 Comparator | Jul 2009 → May 2011 | asthma | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00666679 Comparator | May 2008 → Feb 2009 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 2 | NCT00599534 Comparator | Dec 2007 → Dec 2009 | sleep apnea syndrome | University of Louisville | Withdrawn | No outcome recorded |
| Phase 2 | NCT00543686 Comparator | Aug 2007 → Jan 2009 | childhood onset asthma | Johann Wolfgang Goethe University Hospital | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT06113640 Comparator | Nov 2023 → Nov 2026 expected | Parkinson disease | Mostafa Bahaa | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04351698 Comparator | Oct 2023 → Sep 2024 | obstructive sleep apnea syndrome, sickle cell disease | Great Ormond Street Hospital for Children NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 2/3 | NCT01951898 Comparator | Jun 2012 → Dec 2013 | asthma | Kurume University | Unknown | No outcome recorded |
| Phase 2/3 | NCT00491790 Comparator | Dec 2006 → Jan 2010 | status asthmaticus | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Unknown | No outcome recorded |
| Phase 2/3 | NCT00494572 Comparator | Dec 2006 → Jan 2010 | status asthmaticus | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Unknown | No outcome recorded |
| Phase 2/3 | NCT00311051 Background | Apr 2005 → Apr 2007 | asthma | Research Center Borstel | Withdrawn | No outcome recorded |
| Phase 319 trials | ||||||
| Phase 3 | NCT06429475 Comparator | Jun 2024 → Dec 2028 expected | asthma | University of KwaZulu | Recruiting | No outcome recorded |
| Phase 3 | NCT06340984 Comparator | Jun → Nov 2024 | acne | South Valley University | Unknown | No outcome recorded |
| Phase 3 | NCT05405166 Background | Jun 2022 → Nov 2024 overdue | plasma cell myeloma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05325489 Background | Apr 2022 → Nov 2023 | — | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 3 | NCT04270409 Background | Jun 2020 → Oct 2030 expected | plasma cell myeloma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03770923 Comparator | Oct 2018 → Oct 2026 expected | rheumatoid arthritis | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT03372473 Comparator | Jan → Feb 2016 | childhood onset asthma | Innovacion y Desarrollo de Estrategias en Salud | Completed | No outcome recorded |
| Phase 3 | NCT02483975 Background | Oct 2015 → Jun 2016 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02104674 Comparator | Jun 2014 → Jan 2016 | asthma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01702701 Comparator | Jan 2012 → Jul 2017 | eosinophilic esophagitis | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| Phase 3 | NCT01266772 Comparator | Jan 2011 → Dec 2013 | asthma | Medical University of Lodz | Unknown | No outcome recorded |
| Phase 3 | NCT01142505 Comparator | Nov 2010 → Feb 2014 | asthma | Queen Mary University of London | Completed | No outcome recorded |
| Phase 3 | NCT01089647 Comparator | Sep 2010 → Jun 2014 | obstructive sleep apnea syndrome | Romaker & Associates | Completed | No outcome recorded |
| Phase 3 | NCT00462592 Comparator | Mar 2007 → Jun 2009 | asthma | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00565955 Comparator | Mar 2007 → Oct 2008 | asthma | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00337675 Comparator | Oct 2006 → Aug 2009 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00675285 Comparator | Sep 2005 → Jul 2006 | asthma | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| Phase 3 | NCT00504946 Comparator | Sep 2005 → Mar 2007 | asthma | Medical University of Lodz | Completed | No outcome recorded |
| Phase 3 | NCT00117338 Comparator | Jul 2005 → Mar 2008 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 439 trials | ||||||
| Phase 4 | NCT07532993 Comparator | Sep 2026 → Feb 2027 expected | allergic rhinitis | Liaquat National Hospital & Medical College | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07101445 Background | Sep 2025 → Dec 2026 expected | plasma cell myeloma | Emory University | Recruiting | No outcome recorded |
| Phase 4 | NCT07533565 Comparator | Jul 2024 → Jul 2025 | asthma, cirrhosis of liver | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT06019728 Background | Nov 2023 → Oct 2024 | Fabry disease | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT04762472 Comparator | Sep 2023 → Dec 2024 | coronary atherosclerosis | Chinese University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT04527016 Comparator | Oct 2021 → Jun 2023 | childhood onset asthma | Children's Hospital of Fudan University | Completed | No outcome recorded |
| Phase 4 | NCT04613180 Comparator | Jan 2018 → Dec 2023 | acute bronchiolitis | Samarkand State Medical Institute | Unknown | No outcome recorded |
| Phase 4 | NCT02889809 Background | Jul 2017 → Apr 2021 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02479074 Comparator | Jan 2016 → Feb 2017 | — | Hull University Teaching Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT02494466 Comparator | May 2014 → Jun 2015 | reactive airway disease | Umraniye Education and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01618929 Comparator | Mar 2013 → May 2015 | asthma, food allergy | Hacettepe University | Completed | No outcome recorded |
| Phase 4 | NCT01696214 Comparator | Oct 2012 → May 2015 | asthma | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT01754220 Comparator | Mar → Dec 2012 | — | Association Asthma, Bulgaria | Completed | No outcome recorded |
| Phase 4 | NCT02014532 Comparator | Mar 2012 → Jul 2013 | chronic periodontitis | Tatyasaheb Kore Dental College | Completed | No outcome recorded |
| Phase 4 | NCT01404013 Comparator | Feb 2012 → Aug 2014 | asthma | The First Affiliated Hospital of Guangzhou Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT03369119 Comparator | Aug 2011 → Oct 2012 | acute asthma, bronchitis | Kecioren Education and Training Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01027806 Comparator | Jul 2010 → Aug 2014 | obstructive sleep apnea syndrome | University of Chicago | Terminated | No outcome recorded |
| Phase 4 | NCT01121016 Comparator | Jun 2010 → Jun 2011 | lower respiratory tract disorder | Guangzhou Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01304901 Comparator | Apr → Dec 2010 | acute asthma | Kecioren Education and Training Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00875082 Comparator | Feb 2010 → Sep 2011 | asthma | University of Verona | Completed | No outcome recorded |
| Phase 4 | NCT01016847 Comparator | Jan 2010 → Nov 2013 | asthma | Duke University | Terminated | No outcome recorded |
| Phase 4 | NCT01526161 Comparator | Apr 2009 → Jun 2010 | asthma | Professor Warren Lenney | Completed | No outcome recorded |
| Phase 4 | NCT00912171 Comparator | Jan 2009 → Apr 2010 | obstructive sleep apnea syndrome | University of Bologna | Completed | No outcome recorded |
| Phase 4 | NCT00487773 Comparator | Sep 2007 → Sep 2008 | asthma | Medical University of Lodz | Completed | No outcome recorded |
| Phase 4 | NCT00488176 Comparator | Apr 2007 → Nov 2013 | seasonal allergic rhinitis | Medical University of Lodz | Unknown | No outcome recorded |
| Phase 4 | NCT00559546 Comparator | Mar → Jul 2007 | asthma, atopic eczema, conjunctivitis, seasonal allergic rhinitis | University of Helsinki | Completed | No outcome recorded |
| Phase 4 | NCT00935415 Comparator | Jan 2007 → Aug 2008 | exercise-induced bronchoconstriction | University of Verona | Completed | No outcome recorded |
| Phase 4 | NCT00394355 Comparator | Sep 2006 → Oct 2009 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00380484 Comparator | Sep 2006 → Feb 2008 | asthma | Children´s Clinic, Randers | Completed | No outcome recorded |
| Phase 4 | NCT00351364 Comparator | Jul 2006 → Jul 2010 | acute coronary syndrome, coronary artery disorder | University of Calgary | Terminated | No outcome recorded |
| Phase 4 | NCT00296491 Comparator | Sep 2005 → Oct 2007 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00119015 Comparator | Jul 2005 → Jun 2008 | perennial allergic rhinitis | University of Chicago | Terminated | No outcome recorded |
| Phase 4 | NCT00934713 Comparator | Sep 2004 → Apr 2008 | obstructive lung disease | University of Helsinki | Completed | No outcome recorded |
| Phase 4 | NCT00189462 Comparator | Mar 2004 → Dec 2005 | ear infection, otitis media | Deborah Gentile | Completed | No outcome recorded |
| Phase 4 | NCT00189475 Comparator | Oct 2003 → Jul 2007 | viral respiratory tract infection | Deborah Gentile | Completed | No outcome recorded |
| Phase 4 | NCT00590772 Comparator | May 2003 → Jan 2009 | perennial allergic rhinitis | Penn State University | Completed | No outcome recorded |
| Phase 4 | NCT00641472 Comparator | Oct 2002 → Feb 2005 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00913328 Comparator | Aug 2002 → May 2006 | asthma | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01011452 Comparator | May 2001 → Aug 2004 | acute asthma | University of East Anglia | Completed | No outcome recorded |
| Phase not applicable16 trials | ||||||
| — | NCT06597682 Background | Mar 2025 → Jul 2027 expected | long COVID-19 | Huashan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05959889 Comparator | Mar 2023 → Nov 2024 | breast cancer, chemotherapy-induced toxicity | Damanhour University | Completed | No outcome recorded |
| — | NCT05447039 Comparator | Sep → Nov 2020 | post-COVID-19 disorder | Assiut University | Completed | No outcome recorded |
| — | NCT04621513 Background | Jul 2020 → Dec 2021 | obstructive sleep apnea syndrome | China Medical University Hospital | Unknown | No outcome recorded |
| — | NCT04561687 Comparator | Jan 2020 → Sep 2021 | allergic rhinitis | Shiraz University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT02559388 Comparator | Apr → Aug 2015 | chronic kidney disease | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| — | NCT02303600 Comparator | Aug 2014 → Aug 2015 | — | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| — | NCT02341573 Comparator | Mar 2013 → Jun 2015 | childhood onset asthma | Children's Hospital of Fudan University | Completed | No outcome recorded |
| — | NCT01581710 Comparator | May 2012 → Sep 2015 | asthma | CHA University | Completed | No outcome recorded |
| — | NCT01224964 Comparator | Jan 2011 → Oct 2014 | asthma | Universitaire Ziekenhuizen KU Leuven | Terminated | No outcome recorded |
| — | NCT00655616 Comparator | Aug 2007 → Aug 2009 | asthma | University of Dundee | Completed | No outcome recorded |
| — | NCT00421018 Comparator | Nov 2006 → Apr 2010 | allergic asthma | Karolinska Institutet | Completed | No outcome recorded |
| — | NCT00359073 Comparator | Oct 2006 → Jan 2009 | asthma | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT00379808 Comparator | Jul 2006 → Jul 2009 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| — | NCT00524693 Comparator | Jan 2006 → ? | bronchiolitis | Ziv Hospital | Completed | No outcome recorded |
| — | NCT00319488 Comparator | Feb 2004 → Nov 2006 | asthma, lung disorder | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2009-08-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Provides Update On Generic Singulair® Litigation tevapharm.com ↗ |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 314 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | montelukast | “Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin)...” NCT02578277 ↗299“Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg” NCT02045966 ↗ “The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.” NCT04324918 ↗ “Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: A randomized controlled trial.” PMID 28894551 ↗ Jul 2017 “Montelukast (Singulair ) is a selective leukotriene-receptor antagonist that inhibits the cysteinyl leukotriene 1 receptor.” NCT00551382 ↗ “Any therapy that is prescribed as per asthma guidelines i.e. beclomethasone, budesonide and salbutamol, montelukast etc” NCT06429475 ↗ “Single oral dose of the cocktail probe substrates (caffeine 200 mg, montelukast 10 mg, midazolam 4 mg)” NCT04275115 ↗ “receiving budesonide (BD, 256ug) plus montelukast (MNT, 10 mg) or BD alone (256ug) for 2 weeks” NCT04077892 ↗ “a tablet treatment for asthma called Singulair (montelukast)” NCT00273013 ↗ “Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD” NCT04621513 ↗ “oral montelukast sodium chewable tablets 4mg QD” NCT05325489 ↗ “Montelukast 10mg PO prior to DARZALEX FASPRO®.” NCT05807048 ↗ “Montelukast and Bepotastine Combination” NCT04097951 ↗ “montelukast(4mg od for 3 months)” NCT04527016 ↗ “Montelukast (ML)” NCT01624974 ↗ “Montelukast” NCT02758873 ↗ |
| Known as | Brondilat | ChEMBL registry synonym — accepted as the source's own label CHEMBL787 ↗ |
| Known as | GW483100 | “It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.” NCT02322671 ↗ |
| Known as | MK-476 | ChEMBL registry synonym — accepted as the source's own label CHEMBL787 ↗ |
| Known as | MK0476 | “The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)” NCT00739297 ↗15“MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks” NCT00545324 ↗ “MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks” NCT00380705 ↗ “MK0476, montelukast sodium / Duration of Treatment: 12 Weeks” NCT00398151 ↗ “MK0476, Montelukast Sodium /Duration of Treatment : 14 Days” NCT00394160 ↗ “MK0476, montelukast sodium / Duration of Treatment: 2 Weeks” NCT00446186 ↗ “MK0476, montelukast sodium / Duration of Treatment: 4 weeks” NCT00092144 ↗ “MK0476, montelukast sodium / Duration of Treatment: 8 Weeks” NCT00445107 ↗ “MK0476, montelukast sodium / Duration of Treatment: 4 Weeks” NCT00446056 ↗ “MK0476; montelukast sodium/Duration of Treatment: 16 weeks” NCT00157937 ↗ “MK0476, montelukast sodium / Duration of Treatment: 1 Year” NCT00489346 ↗ “MK-0476, montelukast sodium” NCT00394069 ↗ “MK0476; montelukast sodium” NCT00140881 ↗ “MK0476, montelukast sodium” NCT00395408 ↗ “MK0476, montelukast sodium” NCT00092105 ↗ “MK0476, montelukast sodium” NCT00092885 ↗ |
| Known as | MKT-N2 | “MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium)to Treat Asthma” NCT02029313 ↗ |
| Known as | MLKT | “10 mg of Montelukast (MLKT) was administered orally on Days 1 and 2.” NCT00295022 ↗ |
| Known as | MNT | “receiving budesonide (BD, 256ug) plus montelukast (MNT, 10 mg) or BD alone (256ug) for 2 weeks” NCT04077892 ↗ |
| Known as | MON | “Limited information exists comparing fluticasone propionate/salmeterol combination (FSC) versus montelukast (MON) in patients with coexistent asthma and allergic rhinitis.” PMID 20167147 ↗ Jan 20102“Investigating the efficacy and safety of rupatadine (RUP) versus montelukast (MON) as adjuvant therapy for patients with rheumatoid arthritis (RA).” PMID 34218304 ↗ Jul 2021 “montelukast (MON)” NCT00296491 ↗ |
| Known as | Montelukast (as sodium) | ChEMBL registry synonym — accepted as the source's own label CHEMBL787 ↗ |
| Known as | montelukast (Singulair) | “montelukast (Singulair)” NCT00462592 ↗ |
| Known as | Montelukast monosodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL787 ↗ |
| Known as | Montelukast Oral Tablet | “Drug: Montelukast Oral Tablet” NCT05381207 ↗ |
| Known as | Montelukast sodium | “A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in...” NCT00284856 ↗47“The purpose of this study is to evaluate the effectiveness of adding Montelukast Sodium (singulair®) 10 mg per day to inhaled corticosteroids in adult subjects with uncontrolled asthma.” NCT00755794 ↗ “A 12 Week Multicenter, Open-label, Observational Study to Evaluate the Effectiveness of Montelukast Sodium (Singulair®), 4 or 5 mg/Day in Pediatric Subjects With Uncontrolled Asthma” NCT00832455 ↗ “Montelukast Sodium, used in asthma treatment, is a cysteinyl leukotriene Type 1 antagonist which reduces leukotriene C4, leukotriene D4 and leukotriene E4 synthesis.” NCT02494466 ↗ “Montelukast sodium is a leukotriene-receptor antagonist approved as a controller medication for chronic asthma and allergic rhinitis in children and adults.” PMID 28639856 ↗ Jun 2017 “Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .” NCT02352545 ↗ “Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)” NCT00656058 ↗ “Montelukast sodium (Singulair) will be given at a dose according to body weight.” NCT04474327 ↗ “MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks” NCT00545324 ↗ “MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium)to Treat Asthma” NCT02029313 ↗ “MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks” NCT00380705 ↗ “MK0476, montelukast sodium / Duration of Treatment: 12 Weeks” NCT00398151 ↗ “montelukast sodium (Singulair), for the management of asthma” NCT00162864 ↗ “MK0476, montelukast sodium / Duration of Treatment: 2 Weeks” NCT00446186 ↗ “MK0476, montelukast sodium / Duration of Treatment: 4 weeks” NCT00092144 ↗ “MK0476, montelukast sodium / Duration of Treatment: 4 Weeks” NCT00446056 ↗ “MK0476, montelukast sodium / Duration of Treatment: 8 Weeks” NCT00445107 ↗ “MK0476, Montelukast Sodium /Duration of Treatment : 14 Days” NCT00394160 ↗ “MK0476; montelukast sodium/Duration of Treatment: 16 weeks” NCT00157937 ↗ “MK0476, montelukast sodium / Duration of Treatment: 1 Year” NCT00489346 ↗ “Singulair: Montelukast sodium (leukotriene modulator)” NCT01424124 ↗ “Leukotriene Receptor Antagonist (Montelukast Sodium)” NCT00319488 ↗ “Montelukast sodium is a white to off-white powder.” NCT04885530 ↗ “oral montelukast sodium chewable tablets 4mg QD” NCT05325489 ↗ “Montelukast sodium 5 mg chewable tablets” NCT00092092 ↗ “MK-0476, montelukast sodium” NCT00394069 ↗ “MK0476, montelukast sodium” NCT00395408 ↗ “MK0476, montelukast sodium” NCT00092105 ↗ “MK0476, montelukast sodium” NCT00092885 ↗ “MK0476; montelukast sodium” NCT00140881 ↗ “Drug: montelukast sodium” NCT00770900 ↗ “Drug: montelukast sodium” NCT00911547 ↗ “Drug: Montelukast Sodium” NCT00351364 ↗ “Drug: montelukast sodium” NCT00289874 ↗ “Drug: montelukast sodium” NCT00863317 ↗ “Drug: montelukast sodium” NCT00963469 ↗ “Drug: montelukast sodium” NCT00092989 ↗ “Drug: montelukast sodium” NCT00487773 ↗ “Drug: montelukast sodium” NCT00771160 ↗ “Drug: montelukast sodium” NCT00442338 ↗ “Drug: montelukast sodium” NCT00972738 ↗ “Drug: montelukast sodium” NCT00974571 ↗ “Drug: montelukast sodium” NCT00337675 ↗ “Montelukast Sodium” NCT00636207 ↗ |
| Known as | NSC-759107 | ChEMBL registry synonym — accepted as the source's own label CHEMBL787 ↗ |
| Known as | singulair | “A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic...” NCT00557284 ↗19“A 12 Week Multicenter, Open-label, Observational Study to Evaluate the Effectiveness of Montelukast Sodium (Singulair®), 4 or 5 mg/Day in Pediatric Subjects With Uncontrolled Asthma” NCT00832455 ↗ “Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)” NCT00395304 ↗ “determining how intervention with montelukast (singulair) affects symptoms and the rate of recurrent wheezing.” NCT00115297 ↗ “Montelukast (Singulair) is a drug that has been used for many years to treat asthma.” NCT00656058 ↗ “MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks” NCT00545324 ↗ “MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium)to Treat Asthma” NCT02029313 ↗ “MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks” NCT00380705 ↗ “montelukast sodium (Singulair), for the management of asthma” NCT00162864 ↗ “At the remission stage: Singulair, once daily for 3 months.” NCT02341573 ↗ “Singulair: Montelukast sodium (leukotriene modulator)” NCT01424124 ↗ “montelukast (singulair 10mg, daily)” NCT02110654 ↗ “Montelukast (Singulair®)” NCT01551147 ↗ “montelukast (Singulair)” NCT01536041 ↗ “Montelukast/ Singulair” NCT00511316 ↗ |
| Known as | singular | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00699062 ↗ |
| Action | Inhibit | “Oral leukotriene receptor antagonists (eg montelukast)” NCT00045955 ↗ |
| Modality | Other / unclassified | “leukotriene receptor antagonist (montelukast)” NCT00156819 ↗ |
| Route | Oral | “Oral leukotriene receptor antagonists (eg montelukast)” NCT00045955 ↗ |
| Target | CYP2C8 | “montelukast is an powerful CYP2C8 inhibitor” NCT00453765 ↗ |